Neurocrine Biosciences | NBIX - 股票



金融业
股票价格
USD
资产
USD 5.36B
现金及等价物
USD 332.4M
销售成本
USD 39.4M
流动资产
USD 1.64B
流动负债
USD 874.5M
债务
USD 406.2M
EBIT
USD 219.9M
EBITDA
USD 193.3M
员工
1.8K
EPS每股收益
USD 2.85
股本和储备
USD 3.69B
销售毛利
USD 800.7M
债务利息支出
USD 1.1M
贷款资金
USD 169.5M
市值
USD 15.36B
净收入
USD 144.4M
营业费用
USD 739.1M
营业利润
USD 219.9M
普通股股本
USD 100.55M
PE价格收益
22.1
税前利润
USD 246.8M
销售收入
USD 959M
销售和管理费用
USD 383.1M
股票
USD 104.2M
贸易债权人
USD 691.3M
应收帐款人
USD 887M


股票 更改 日
AbbVie USD 5.13B 78M 2026-06
Acadia Pharmaceuticals USD 108.67M 77.1M 2026-06
Agios Pharmaceuticals USD 35.75M 665K 2026-06
ALKERMES USD 298.96M 37.75M 2026-06
Alnylam Pharmaceuticals USD 97.11M 103.04M 2026-06
Amgen USD 6.22B 34M 2026-06
Biogen USD 2.38B 435.3M 2026-06
BioMarin Pharmaceutical USD 1.78B 509.3M 2026-06
Cytokinetics USD 380K 226K 2026-06
Exelixis USD 28.73M 2.12M 2026-06
Gilead Sciences USD 1.91B 140M 2026-03
Halozyme Therapeutics USD 137.14M 18.33M 2026-06
Incyte USD 112.54M 3.08M 2026-06
Ionis Pharmaceuticals USD 50.83M 45.28M 2026-06
Nektar Therapeutics USD 14.46M 1.78M 2024-06
Neurocrine Biosciences USD 104.2M 39.7M 2026-06
Pfizer USD 9.94B 722M 2026-06
Regeneron Pharmaceuticals USD 3.08B 19.3M 2026-06
Repligen USD 186.6M 7.35M 2026-06
Rigel Pharmaceuticals USD 13.3M 2.88M 2025-09
Sarepta Therapeutics USD 904.27M 96.84M 2026-06
Teva Pharmaceutical Industries USD 3.18B 3M 2026-03
Ultragenyx Pharmaceutical USD 59M 4M 2026-06
Vertex Pharmaceuticals USD 1.77B 1.6M 2026-06